Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.

Oncogene·2025
Same author

A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencing.

Briefings in bioinformatics·2025
Same author

Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy.

Journal of translational medicine·2024
Same author

Mutational landscape of inflammatory breast cancer.

Journal of translational medicine·2024
Same author

Long-term survival of <i>NPM1</i> AML treated with intensive chemotherapy with extensive molecular data available.

Leukemia & lymphoma·2024
Same author

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.

Journal of translational medicine·2023

Related Experiment Video

Updated: Jul 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

How basal are triple-negative breast cancers?

François Bertucci1, Pascal Finetti, Nathalie Cervera

  • 1Centre de Recherche en Cancérologie de Marseille, Département d'Oncologie Moléculaire, Institut Paoli-Calmettes (IPC) et UMR599 Inserm, Marseille, France. bertuccif@marseille.fnclcc.fr

International Journal of Cancer
|April 10, 2008
PubMed
Summary

The basal breast cancer subtype is transcriptionally homogeneous and aggressive. Triple-negative breast cancer (TNBC) is often used as a proxy for basal BC, but this study shows TNBC is more heterogeneous, impacting clinical trial selection.

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Related Experiment Videos

Last Updated: Jul 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Basal breast cancer (BC) is a transcriptionally homogeneous and aggressive subtype.
  • Basal BC is often clinically approximated by triple-negative (TN) status using immunohistochemistry (IHC).
  • Current systemic therapeutic strategies are being developed for basal BCs, with TNBCs frequently selected for clinical trials.

Purpose of the Study:

  • To assess the correlation and homogeneity between the basal molecular subtype and the TN phenotype in breast cancer.
  • To evaluate the clinical and molecular heterogeneity within TNBCs compared to basal BCs.
  • To inform patient selection for ongoing and future clinical trials targeting basal BC.

Main Methods:

  • Gene expression profiling to define basal and nonbasal BC subtypes.
  • Immunohistochemistry (IHC) to define triple-negative (TN) phenotype.
  • Analysis of 172 TN BCs and 160 basal BCs using uni- and multivariate analyses.

Main Results:

  • TNBCs are more heterogeneous than basal BCs, encompassing both basal and nonbasal molecular subtypes.
  • Significant molecular and histoclinical differences exist between basal and nonbasal tumors within the TNBC group.
  • Discrepancies were noted in the expression of mRNA targets relevant to ongoing therapeutic trials.

Conclusions:

  • The assimilation of basal BCs with TNBCs for clinical trials may lead to misinterpretation and suboptimal patient stratification.
  • TNBCs represent a heterogeneous group, necessitating more precise molecular markers for basal BC identification.
  • Clinical trial designs and patient selection strategies require re-evaluation to accurately target basal BCs.